Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note published on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock.

A number of other research analysts have also weighed in on APTO. HC Wainwright reaffirmed a buy rating and set a $7.00 target price on shares of Aptose Biosciences in a report on Friday, June 14th. Canaccord Genuity Group reduced their target price on Aptose Biosciences from $15.00 to $6.00 and set a buy rating for the company in a report on Thursday, May 16th. Finally, Piper Sandler reaffirmed an overweight rating and set a $5.00 target price on shares of Aptose Biosciences in a report on Wednesday, April 3rd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $14.83.

Aptose Biosciences Price Performance

APTO stock opened at $0.74 on Friday. The firm has a market capitalization of $13.46 million, a PE ratio of -0.12 and a beta of 1.27. Aptose Biosciences has a twelve month low of $0.71 and a twelve month high of $5.10. The stock has a 50-day simple moving average of $1.03 and a two-hundred day simple moving average of $1.57.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.09. On average, equities research analysts anticipate that Aptose Biosciences will post -2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.16% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is currently owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.